Nothing Special   »   [go: up one dir, main page]

BR112022009317A2 - Anticorpos de cd73 biparatópicos - Google Patents

Anticorpos de cd73 biparatópicos

Info

Publication number
BR112022009317A2
BR112022009317A2 BR112022009317A BR112022009317A BR112022009317A2 BR 112022009317 A2 BR112022009317 A2 BR 112022009317A2 BR 112022009317 A BR112022009317 A BR 112022009317A BR 112022009317 A BR112022009317 A BR 112022009317A BR 112022009317 A2 BR112022009317 A2 BR 112022009317A2
Authority
BR
Brazil
Prior art keywords
biparatopic
antibodies
methods
antigen binding
binding proteins
Prior art date
Application number
BR112022009317A
Other languages
English (en)
Inventor
E Stefano James
Zhou Yenfang
Lord Dana
Radosevic Katarina
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112022009317A2 publication Critical patent/BR112022009317A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS DE CD73 BIPARATÓPICOS. A presente invenção refere-se a proteínas de ligação ao antígeno anti-CD73. Proteínas de ligação ao antígeno anti-CD73 biparatópicas são fornecidas. Métodos de inibição da atividade de CD73 e métodos de tratamento de doenças e distúrbios mediados por CD73 também são fornecidos.
BR112022009317A 2019-11-15 2020-11-13 Anticorpos de cd73 biparatópicos BR112022009317A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962936119P 2019-11-15 2019-11-15
US202063023542P 2020-05-12 2020-05-12
US202063086982P 2020-10-02 2020-10-02
PCT/US2020/060434 WO2021097223A2 (en) 2019-11-15 2020-11-13 Biparatopic cd73 antibodies

Publications (1)

Publication Number Publication Date
BR112022009317A2 true BR112022009317A2 (pt) 2022-08-09

Family

ID=73790235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009317A BR112022009317A2 (pt) 2019-11-15 2020-11-13 Anticorpos de cd73 biparatópicos

Country Status (13)

Country Link
US (1) US20220403041A1 (pt)
EP (1) EP4058150A2 (pt)
JP (1) JP2023503846A (pt)
KR (1) KR20220100929A (pt)
CN (1) CN115003385A (pt)
AU (1) AU2020384305A1 (pt)
BR (1) BR112022009317A2 (pt)
CA (1) CA3161717A1 (pt)
CO (1) CO2022008204A2 (pt)
IL (1) IL292959A (pt)
MX (1) MX2022005866A (pt)
PH (1) PH12022551150A1 (pt)
WO (1) WO2021097223A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
CN115135341A (zh) 2020-01-03 2022-09-30 因赛特公司 抗cd73抗体及其用途
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2023236971A1 (zh) * 2022-06-08 2023-12-14 上海华奥泰生物药业股份有限公司 Cd73抗体鸡尾酒疗法
CN116903744B (zh) * 2022-08-12 2024-03-08 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
KR20020047132A (ko) * 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EA032681B1 (ru) 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
SG11201701341UA (en) 2014-10-10 2017-03-30 Innate Pharma Cd73 blockade
SI3218406T2 (sl) * 2014-11-10 2025-05-30 Medimmune Limited Vezavne molekule specifične za CD73 in njihove uporabe
WO2017118613A1 (en) 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
KR20180118725A (ko) * 2016-03-04 2018-10-31 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP3481869A4 (en) * 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. ANTI-CD73 ANTIBODIES
NZ753714A (en) * 2017-01-24 2023-03-31 I Mab Biopharma Co Ltd Anti-cd73 antibodies and uses thereof
EP3609580A4 (en) * 2017-04-09 2021-03-24 Combio Pharmaceutical, Inc. BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES WITH COMMON LIGHT CHAIN AND METHOD OF USE
CA3063344A1 (en) * 2017-05-23 2018-11-29 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Novel cd73 antibody, preparation and uses thereof
WO2018237173A1 (en) * 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US11312783B2 (en) * 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
AU2019231791B2 (en) * 2018-03-09 2022-08-11 Agenus Inc. Anti-CD73 antibodies and methods of use thereof
US11299550B2 (en) * 2018-03-09 2022-04-12 Phanes Therapeutics, Inc. Anti-CD73 antibodies and uses thereof

Also Published As

Publication number Publication date
KR20220100929A (ko) 2022-07-18
MX2022005866A (es) 2022-08-15
PH12022551150A1 (en) 2023-10-09
EP4058150A2 (en) 2022-09-21
US20220403041A1 (en) 2022-12-22
CA3161717A1 (en) 2021-05-20
JP2023503846A (ja) 2023-02-01
AU2020384305A1 (en) 2022-06-30
CN115003385A (zh) 2022-09-02
WO2021097223A2 (en) 2021-05-20
IL292959A (en) 2022-07-01
CO2022008204A2 (es) 2022-06-21
WO2021097223A3 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
MX2019005911A (es) Anticuerpos anti_cd137 novedosos y usos de estos.
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
BR112022003956A2 (pt) Anticorpos anti-cd73
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MX2018009581A (es) Inmunoglobulina con fabs en tandem y sus usos.
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
MX2019004779A (es) Composicion farmaceutica para tratamiento y/o prevencion de cancer.
BR112012022102A2 (pt) polipeptídeos de ligação a a-beta.
BR112018068678A2 (pt) anticorpos anti-mica
WO2018031490A3 (en) Anti-ox40 binding proteins
SA520420582B1 (ar) Cd3 أجسام مضادة خاصة لـ واستخداماتها
EA202092420A1 (ru) Антитело против pd-l1 и его применение
MX392158B (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
EA201990895A1 (ru) Антитела к о1 и варианты их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins